From owner-repertoires@net.bio.net Mon May 03 23:00:00 1999 Path: biosci!biosci!not-for-mail From: Tara Dyson Newsgroups: bionet.molecules.repertoires Subject: Current Opinion in Oncologic, Endocrine & Metabolic Investigational Date: 4 May 1999 02:56:07 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 65 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net ANNOUNCING - CURRENT OPINION IN ONCOLOGIC, ENDROCRINE & METABOLIC INVESTIGATIONAL DRUGS - A NEW REVIEW JOURNAL FREE SAMPLE COPIES AVAILABLE Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs is a new bimonthly review journal published by Current Drugs Ltd, which covers all aspects of research into anticancer, endocrine and metabolic disease therapies. The journal provides a comprehensive and up-to-date source of peer-reviewed information on trends and advances in drug discovery and development for cancer, diabetes, osteoporosis and metabolic and fertility disorders. The scope of coverage will include advances in the understanding of disease etiology, from both a genomic and environmental perspective, new trends and targets in disease treatments, as well as the status of compounds advancing through the clinical trial process. Edited by Stanley T Crooke, Herbert M Pinedo and Franklyn F Bolander, the journal is designed to combat the proliferation of the scientific literature by giving the reader an intelligent overview of the important developments across the entire subject. Its contents are divided into six major sections, each of which is reviewed in turn throughout the year. Endocrine and metabolic drugs DNA replication inhibitors Immunomodulatory drugs Nucleotide metabolism Non-nucleotide metabolism Cell signaling/hormonal drugs Contributions from internationally recognized researchers are all invited and peer-reviewed by an Editorial Board of distinguished members of the scientific community. The views of experts in the form of editorial overviews, review articles, drug evaluations, annotated paper and patent coverage are contained in each issue. For further information, see the Current Drugs website http://www.current-drugs.com To request your FREE SAMPLE COPY mailto:cooemsamp@cursci.co.uk and supply us with your name, company, address, telephone number and email details. Kind regards Tara Dyson Editorial Director Current Drugs Ltd Middlesex House 34-42 Cleveland Street London W1P 6LB UK Tel: +44-171-580-8393 Fax: +44-171-580-5646 Email: tara@cursci.co.uk http://www.current-drugs.com From owner-repertoires@net.bio.net Mon May 03 23:00:00 1999 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.molecules.repertoires Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 4 May 1999 02:30:30 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 236 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <199904280900.CAA17731@net.bio.net> NNTP-Posting-Host: net.bio.net (LAST REVISION: 30-JUL-95) This BIOSCI "miniFAQ" is designed to answer the questions that come up the *most frequently*. The main BIOSCI FAQ (Frequently Asked Questions) is accessible on the World Wide Web at URL http://www.bio.net/. If you can not find an answer to your question in this or other documentation, the BIOSCI technical support staff answers e-mail queries sent to biosci-help@net.bio.net We can only answer questions about the use of the newsgroups and mailing lists. We unfortunately do not have the staff to do Internet information searches or answer scientific questions. Please post those to the appropriate BIOSCI/bionet newsgroups. Contents: -------- 0) BIOSCI NEEDS YOUR SUPPORT!! 1) Using the WWW to access the BIOSCI/bionet newsgroups. 2) What to do about "spams," i.e., junk mail, ads, etc. 3) Examples of subscribing and unsubscribing to the mailing lists. 4) The BIOSCI user address and research interest directory. 0) BIOSCI NEEDS YOUR SUPPORT!! ------------------------------ BIOSCI's government funding has been expended, and we are now operating solely from advertising revenue that we have raised from our Web site at http://www.bio.net/. We need just a few minutes of your time to help us serve you. You can do two important things which will take very little time for you individually and will immensely help us continue to help you. First, please use our WWW system at http://www.bio.net/ to access the archives. You can post or reply to messages via your Web browser as described in item #1 below. Your usage helps attract sponsors. If you contact any of our sponsors, please be sure to thank them for supporting BIOSCI. It is critical for them to get this feedback if they are to continue their sponsorship for the long term. Second, if you work for a company or organization that provides products or services of interest to the biology community, please pass this message on to your marketing or marketing communications department or other appropriate group. Please ask them to help support BIOSCI by sponsoring our Web site and explain the uses and benefits of the system to the biology community. If they are interested, they can then contact us for further information at our tech support address, biosci-help@net.bio.net. 1) Using the WWW to access the BIOSCI/bionet newsgroups. -------------------------------------------------------- As of 10 December 1995, all BIOSCI/bionet full newsgroups are accessible through the World Wide Web (WWW) at URL http://www.bio.net. One can read and reply publicly or privately to both recent postings and archived messages through one's Web browser if it is configured properly to send e-mail. Each newsgroup is equipped with its own WAIS index. The main BIOSCI home page also has access to the BIO-JOURNALS Table of Contents database WAIS index and the BIOSCI user address database described in another item further below. 2) What to do about "spams," i.e., junk mail, ads, etc. ------------------------------------------------------- BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), mailing lists, and a hypermail archive at URL http://www.bio.net/. The same postings are distributed on all media (except for a small number of mailing-list-only groups at net.bio.net). Unfortunately it is becoming a despicable practice on the Internet (by a few people out to make a fast buck) to do automated mass postings to thousands of newsgroups and mailing lists. These attempts to grab free advertising are refered to as "spams" in the usual, somewhat boneheaded, net terminology. USENET is more susceptible to this practice, and many spams originate on the USENET groups and then are passed on to the mailing lists. However, spammers also get lists of mailing addresses and hit these too, so neither medium is immune. What should you do personally if you get junk mail? --------------------------------------------------- Just delete it and move on without reading it further. Filing a protest is becoming increasingly useless because spammers are often disguising the addresses where the messages are sent from. Unless you really understand Internet mail systems, your attempt at protest by sending replies to the message will often end up being sent to the address of an innocent person that the spammer is victimizing. What can BIOSCI/bionet do to protect its newsgroups? ---------------------------------------------------- The only solution currently available is to moderate the newsgroup. If this newsgroup is already moderated, then you are in good shape. Moderation protects the USENET distribution from about 95% of the spams that are being sent to date and protects the mailing lists completely. Moderation means, however, that someone has to take the time to review each message before it goes out. We have set up software here that simply allows the moderator to forward to an address at net.bio.net messages that (s)he wishes to have distributed. This takes no more time than that needed to read the message and pass it on, say about 1 min. per message. Most newsgroups currently have a discussion leader who is responsible for their newsgroup. The discussions leaders and their e-mail addresses are listed in the BIOSCI Information Sheet which is available on the Web at http://www.bio.net/. If a newsgroup is being hit with too many junk postings, please contact the discussion leader for that group and see if there is interest in moderating the group. Please do not assume that by simply posting a complaint to the newsgroup itself, anyone on the BIOSCI staff will act on your complaint. With close to 100 newsgroups to run, the BIOSCI staff has to rely on the discussion leaders of each newsgroup to report problems directly to us at biosci-help@net.bio.net. We will moderate any of our newsgroups if the discussion leader tells us that the readership of the group wishes to do so and if a moderator is willing to do the work. For most BIOSCI/bionet groups, this entails only a few minutes of work each day. Moderating a newsgroup will resolve probably 95% of the junk postings on the USENET distribution. Unfortunately there are easy ways for determined spammers to override the moderation mechanism on USENET, but we can protect our e-mail subscribers from unwanted postings if the newsgroup is moderated. You can also access our newsgroups over the WWW at URL http://www.bio.net. While this Web interface will not stop spammers from trying to post to the groups, this will give you yet another way, besides using USENET news, to keep the junk out of your personal mail files. For those of you with local USENET news systems, the Web interface will also give you faster access to new newsgroups and recent postings. 3) Examples of subscribing and unsubscribing to the mailing lists. ------------------------------------------------------------------ PLEASE NOTE: The BIOSCI management does NOT act on subscription/unsubscription requests that are posted improperly to the newsgroups and mailing lists. People who do this only bother everyone on the lists to no avail. Please be sure to follow the proper procedures below. Gory details are in the BIOSCI Information sheets on the Web at http://www.bio.net. Below we give an example utilizing the METHODS-AND-REAGENTS list at both of our two BIOSCI sites: Users in the Americas and Pacific Rim countries who use the BIOSCI ------------------------------------------------------------------ node at computer net.bio.net: ---------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@net.bio.net. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to biosci-server@net.bio.net. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Do NOT put your e-mail address or other text on these lines. The server only allows you to cancel your subscription if the address on your mail header matches the address on our mailing list. Please ask for help at biosci-help@net.bio.net if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. Users in Europe, Africa, and Central Asia who use the BIOSCI node at -------------------------------------------------------------------- computer daresbury.ac.uk (also known as dl.ac.uk): ------------------------------------------------- To subscribe and unsubscribe to/from the BIOSCI lists, you need to specify the full USENET newsgroup name with "bionet-news." prepended. The USENET newsgroup names are listed in the BIOSCI Information sheet on the Web at http://www.bio.net/. For the METHODS-AND-REAGENTS list the USENET newsgroup name is bionet.molbio.methds-reagnts, thus the appropriate commands are sub bionet-news.bionet.molbio.methds-reagnts unsub bionet-news.bionet.molbio.methds-reagnts These commands are included in a message addressed to mxt@dl.ac.uk, NOT to the newsgroup mailing addresses. As usual, include the text in the body of the message as text on the Subject: line is ignored. To unsubscribe from all the lists at the UK node, use unsub bionet-news Please note that if the address in the list is different than the one in your mail message header, you will not be able to unsubscribe by this method. If you have problems, please mail biosci@daresbury.ac.uk. 4) The BIOSCI user address and research interest directory. ----------------------------------------------------------- Please take this opportunity to add your name, address, and research interest information to the BIOSCI User Address Database if you have not already done so. You can fill out the address form directly through our Web page at URL http://www.bio.net/adrform.html. The address database is reindexed nightly for WWW access (the URL is http://www.bio.net/). If you are not directly on the Internet but can reach it by e-mail, please use our waismail server to access the user directory. waismail use is described above. You can also request a user address form by e-mail from biosci-help@net.bio.net. Please check your database entry from time-to-time to see if your address information is still up-to-date. Because of our limited personnel resources, we ask that you resubmit a *complete* form to revise your entry; we only replace complete entries and do not have resources to edit old forms. From owner-repertoires@net.bio.net Tue May 04 11:05:00 1999 Path: biosci!biosci!not-for-mail From: "Dr. Shu-Kun Lin" Newsgroups: bionet.molecules.repertoires Subject: Copyright new policy and invitation, Molecules (ISSN 1420-3049) Date: 4 May 1999 05:05:42 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 43 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <372A18EA.8C7DD87B@mdpi.org> NNTP-Posting-Host: net.bio.net (Excuse me for sending to multiple mailing lists) The electronic journal Molecules (http://mdpi.org/molecules/, vol.4, 1999) will do the following, in addition to its recognized unique editorial policy, high publication standard, and free online subscription. 1. Starting from June 1999, we will replace the copyright footnote by "(c) 1999 by the authors. Reproduction of this article, by any means, is permitted for noncommercial purposes". I encourage authors to freely distribute by e-mail and store on the internet their pdf file or html file of their Molecules paper. 2. On behalf of the editorial board, I am inviting qualified chemists to serve as editors from all countries. The existing Editorial Board will remain as the advisory board. Because Molecules is a non-profit and high standard journal we plan to share the editorial task among a reasonably large number of editors. Every editor will be responsible for inviting and editorial handling 5 or more papers per year. The communications among the authors, referees and the editors will be on the internet. Please recommend qualified chemists to me or inform me your own interest in this voluntary service. Please provide the full address, e-mail and the website or the brief version of CV. The final decision regarding the acceptance of paper will be made by the Editor-in-Chief in Switzerland. The necessary English corrections, layout and final production will also be managed in Switzerland. Therefore, we are ready to make Molecules a major international journal of experimental chemistry, capable of considering and publishing a very large number of high quality papers. 3. In addition to Molecules' Molbank section (http://mdpi.org/molbank/) of short notes, I will launch two new special sections of "Bioactive Compounds" mini-reviews and "Hazardous Compounds" of safety and accident reports, publishing one short paper for one molecular structure. Looking forward to hearing from you. Shu-Kun Lin Managing Editor Molecules (http://mdpi.org/molecules/) Lin@mdpi.org, http://mdpi.org/lin/ From owner-repertoires@net.bio.net Tue May 04 11:13:00 1999 Path: biosci!biosci!not-for-mail From: Duaniqng Pei Newsgroups: bionet.molecules.repertoires Subject: Postdoc Date: 4 May 1999 05:13:04 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 26 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <199904302251.XAA04921@listserv.rl.ac.uk> NNTP-Posting-Host: net.bio.net A postdoctoral position is open immediately to characterize a newly identified MMP--MT5-MMP in the brain and central nerve system. The candidate is expected to join a ongoing project aim at the elucidation of MT5-MMP function by employing state of the art technologies such as gene-knockout and transgenics. The successful candidate must be a US citizen or PR holder (greencard) and graduated from a Ph.D. program in chemistry or any of the biomedical disciplines. Starting salary is $25,000 with benefits. For further information, please contact: Duanqing Pei, Ph.D. at 612-626-1468 by phone or peixx003@tc.umn.edu. Duanqing Pei, Ph.D. Assistant professor of Pharmacology 3-249 Millard Hall 435 Delaware St. S.E. University of Minnesota Minneapolis, MN 55455-0347 Tel: 612-626-1468 Fax: 612-625-0649 E-mail: peixx003@tc.umn.edu http://www.pharmacology.med.umn.edu/ From owner-repertoires@net.bio.net Tue May 04 11:16:00 1999 Path: biosci!biosci!not-for-mail From: Dori Luzbetak Newsgroups: bionet.molecules.repertoires Subject: MDL Acquires Interactive Simulations, Inc. Date: 4 May 1999 05:16:28 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 25 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <8E13FBBA26A9DA119ED400A0C9AB2CE5F92628@shepherd.mdli.com> NNTP-Posting-Host: net.bio.net MDL Information Systems, Inc. announced today that it has acquired the assets of Interactive Simulations, Inc., a leading provider of 3D structure visualization software and productivity tools for the biotechnology, pharmaceutical, and chemical research industries. The acquisition of the San Diego-based firm broadens MDL's offering of decision support tools for drug design and chemical research. For more information, see MDL's Web site. Go directly to http://www.mdli.com/info/news990430-MDL-ISI.html, or go to http://www.mdli.com and select Our Company > Press Releases. For more information about Interactive Simulations, Inc., go to http://www.intsim.com. Dori Luzbetak Web Communications Manager MDL Information Systems, Inc. 14600 Catalina Street San Leandro, CA 94577 Email: dori@mdli.com From owner-repertoires@net.bio.net Tue May 04 11:20:00 1999 Path: biosci!biosci!not-for-mail From: "Robert W. Colman" Newsgroups: bionet.molecules.repertoires Subject: Postdoctoral position Date: 4 May 1999 05:20:18 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 21 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <199905010526.GAA05518@listserv.rl.ac.uk> NNTP-Posting-Host: net.bio.net A postdoctoral position is open immediately to characterize a newly discovered inhibitor of angiogenesis derived from a plasma protein which is inportant in enhancing urokinase dependent proteolysis.The candidate expected to join a ongoing project employing state of the art technologies such as recombinant proteins surface plasmon resonance and cell biological approches The successful candidate must be a US citizen or PR holder (greencard) and graduated from a Ph.D. program in biochemistry or any of the biomedical disciplines. Starting salary is $25000-41000=20 with benefits depending on years after PhD. For further information, please contact: Robert W Colman at 215-707-4665 by phone or colmanr@astro.temple.edu From owner-repertoires@net.bio.net Wed May 05 07:57:00 1999 Path: biosci!biosci!not-for-mail From: Mike Clark Newsgroups: bionet.molecules.repertoires Subject: Humanized, Reshaped, Humouse antibodies? Date: 5 May 1999 01:57:31 -0700 Organization: Cambridge University, Department of Pathology. Lines: 52 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <7gp15r$as9@net.bio.net> NNTP-Posting-Host: net.bio.net I am about to write a review on the topic of antibody humanization and would be interested in any views, comments, on my thoughts below. Particularly if backed up with experimental evidence! As someone who has been heavily involved in the humanisation of monoclonal antibodies for therapy I have become increasingly frustrated at the number of claims and counter claims (mainly from commercial organisations) that one method of producing human or humanized antibodies produces antibodies which are "less immunogenic because they are more human" compared to another. Methods include humanisation of rodent antibodies by CDR grafting, framework grafting, veneering, resurfacing, etc versus the production of antibodies using human V-regions in phage libraries or alternatively mice transgenic for human V-regions. Unfortunately there is in my opinion little or no scientific evidence to support these claims! I guess that it is difficult to justify commercial costs as well as perhaps gain ethical approval to prepare several similar antibodies by the alternative methods and to then treat enough patients to compare antiglobulin responses and thus test the claims in a proper scientific manner. It seems that most of these claims are based on the "opinion" that the more human an antibody sequence is the less immunogenic it will be in humans. However contrary to this experimental evidence demonstrates that it is possible to raise anti-idiotypic antibodies in animal models and it is also possible to tolerise animals to "foreign" immunoglobulins. Of course the whole concept of humanisation of antibodies for therapy is based upon the hypothesis that the immune system discriminates on a self versus non-self basis. Of course if like me you also wish to try and take account of the alternative view of danger versus non-danger then you come to different conclusions. So are antibodies which are destructive in vivo ie ones which bind to Fc receptors, activate complement and cause cell killing, likely to be more immunogenic than antibodies which do not independent of how "human" they are? Any comments, suggestions, references I should consider? Cheers, Mike Clark, -- o/ \\ // || ,_ o M.R. Clark, PhD. Division of Immunology <\__,\\ // __o || / /\, Cambridge University, Dept. Pathology "> || _`\<,_ // \\ \> | Tennis Court Rd., Cambridge CB2 1QP ` || (_)/ (_) // \\ \_ Tel.+44 1223 333705 Fax.+44 1223 333875 From owner-repertoires@net.bio.net Wed May 05 08:06:00 1999 Path: biosci!biosci!not-for-mail From: Steve Heller Newsgroups: bionet.molecules.repertoires Subject: ChemInt'99 Announcement Date: 5 May 1999 02:06:16 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 66 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net This note is a reminder that the deadline for web Abstract Submissions for possible oral presentations for the Chemistry and the Internet (ChemInt'99) meeting is June 1, 1999. After June 1 all abstarcts submitted and accepted will be for the poster session only. All accepted abstracts are currently available on the meeting web site - www.chemint.org The ChemInt'99 meeting is being held in at Georgetown University in Washington DC on September 25-27, 1999. The program of invited speakers and panel members of the 3 panel sessions is available on the meeting web site - www.chemint.org You are urged to look at the program and to consider submitting a poster paper to the meeting. A number of poster papers submitted by June 1 will be selected for oral presentation at the meeting. The main lecturers for the meeting will be: Alan Arnold, University College (UNSW) Steven Bachrach, Northern Illinois University Robert Bovenschulte, ACS Stephen Boyer, IBM Karl Harrison, Oxford University Clemens Jochum, Deutsche Bank Gary Mallard, NIST Tom Pierce, Rohm & Haas Jerome Reichman, Vanderbilt Achim Zielesny, Bayer AG Steven S. Zumdahl, University of Illinois at Urbana-Champaign The (current) corporate sponsors for the meeting are: ChemWeb and the Internet Journal of Chemistry Technical Sponsors are: ACS CINF Division ACS COMP Division The Chemical Structure Association (CSA) Georgetown University - Department of Chemistry International Union of Pure and Applied Chemistry (IUPAC) Japan Association for International Chemical Information (JAICI) Special Libraries Association (SLA) Chemistry Division Royal Society of Chemistry (RSC) Steve Heller Steve Heller, Guest Researcher NIST/SRD, Mail Stop: 820/113 820 Diamond Avenue, Room 101 Gaithersburg, MD 20899-2310 USA E-mail: chem@feldmann.nist.gov From owner-repertoires@net.bio.net Thu May 06 07:33:00 1999 Path: biosci!biosci!not-for-mail From: Mike Clark Newsgroups: bionet.molecules.repertoires Subject: Re: Humanized, Reshaped, Humouse antibodies? Date: 6 May 1999 01:33:29 -0700 Organization: Cambridge University, Department of Pathology. Lines: 101 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <7grk4p$rn9@net.bio.net> References: <37308C09.1C08@mail.tju.edu> NNTP-Posting-Host: net.bio.net In article <37308C09.1C08@mail.tju.edu>, mark wrote: > Mike Clark wrote: > > > > I am about to write a review on the topic of antibody humanization and > > would be interested in any views, comments, on my thoughts below. [snipped] > > > Great> I have wondered about that too. Mark thanks for your comments but I will try to expand a little on my first posting whilst answering your reply. > What is the status of human antibodies as opposed to humanized ones? The first problem I have is the definition of a human antibody versus a humanized antibody. If I isolated a rodent antibody and found that the CDRs were identical to an isolated human antibody but the frameworks were different would a reshaped or CDR grafted version of the rodent antibody which used the same frameworks as the other be human? I would claim I think quite reasonably that it is because the sequences of the reshaped or humanized antibody is identical to the 'isolated human' antibody. Clearly of course I could also quite reasonably claim that it is a humanized antibody because that is how I made it. So in some circumstances humanised antibodies can also be human antibodies! Alternatively take a different example. I isolate a human antibody from one individual human and put it into another human who lacks the V-gene which encodes the antibody (such V-genes can be readily identified from the Tomlinson 'V-Base' directory). The antibody is both human but it is also 'foreign' to the recipient. Now is it more or less 'foreign' than a humanised rodent antibody which differed by the same number of amino acids from the closest V-gene in the recipient? And another example. Take an antibody made by a human B-cell which has undergone somatic mutation and put it into an identical twin in which the same somatic mutation may not have occurred. The antibody can again be defined as both 'human' and yet is still 'foreign' to the recipient at the same time. ie 'human' does not mean the same as 'self'. Can you see the points I am trying to make? The definitions of human, rodent, humanized, reshaped, foreign etc (all commonly used terms in the field of antibody engineering) merely refer to the process and the context by which the antibodies are produced and used. However what we really want to know is are they immunogenic? The point I am trying to get at is that this is not necessarily dependent upon how the antibody is made. > Are phage libraires available that are totally human sequences? Yes there are. But if you then vary the CDR sequences in the library to mimic somatic mutation are they still 'totally human sequence'? > What results are known from the studies with the anti-TNF antibodies? They are immunogenic in at least some of the recipients. To expand further the rat IgG2b CD52 antibody CAMPATH-1G is very immunogenic in most patients.. The reshaped (CDR-grafted) human IgG1 antibody is much less immunogenic (Ah success, humanisation works!) > What about all the IVIG that has been given. Many would claim that at least some of the actions of IVIG can be attributed to idiotype antidiotype interactions! > Are there any responses to these therapies? markH > Again I make the point that some chimaeric antibodies are not very immunogenic in humans whereas others are. Is this merely a reflection of how 'human' the sequences are or is another possibility that the immune system of the recipient sees some antibodies as 'less dangerous' than others? Again I make the point I made in my last posting that this concept of purely 'self versus non-self' discrimination as a basis for antibody humanisation may be fundamentally flawed if you don't also take into account the concept of 'danger versus non-danger'. If I wanted to raise a rodent anti-idiotype antibody to a rodent monoclonal antibody there are many immunisation protocols which I could use which are likely to work [eg use an adjuvant or couple the antibody to a protein such as KLH etc etc]. (The last method is how we made an anti-idiotype to our rat monoclonal antibody CAMPATH-1G). The trick is to make the antibody look 'dangerous'. Mike Clark, -- o/ \\ // || ,_ o M.R. Clark, PhD. Division of Immunology <\__,\\ // __o || / /\, Cambridge University, Dept. Pathology "> || _`\<,_ // \\ \> | Tennis Court Rd., Cambridge CB2 1QP ` || (_)/ (_) // \\ \_ Tel.+44 1223 333705 Fax.+44 1223 333875 From owner-repertoires@net.bio.net Thu May 06 08:23:00 1999 Path: biosci!biosci!not-for-mail From: "Judy Y. Zhu" Newsgroups: bionet.molecules.repertoires Subject: images: microtubule Date: 6 May 1999 02:23:21 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 18 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <3.0.1.32.19990505161219.0085f751@molec.com> NNTP-Posting-Host: net.bio.net In-vitro Studies of Microtubules Structures using MAC Mode AFM J. Zhu+, J. Hartman*, R. Case*, S. Rice*, & R. Vale* +Molecular Imaging Corp., * Howard Hughes Medical Institute and the Department of Pharmacology and Biochemistry, Univ. of California, San Francisco. http://www.molec.com/biology/microtubules/index.html From owner-repertoires@net.bio.net Thu May 06 14:27:00 1999 Path: biosci!biosci!not-for-mail From: Alberto Gobbi Newsgroups: bionet.molecules.repertoires Subject: Job opening: Postdoc, Cheminformatics at Novartis Crop Protection , Date: 6 May 1999 08:27:45 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 53 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <304CAD40233FD211837B00005A4224028BD5D1@pp-timon-chbs.cp.chbs> NNTP-Posting-Host: net.bio.net Dear Colleagues, please find below the description of a job opening at Novartis Crop Protection in Basel Switzerland. Please forward this description to anybody who might be interested. Thanks, Alberto Gobbi Novartis Crop Protection in Basel Switzerland has one Job opening for a postdoctoral position in the area of Cheminformatics. Please find details below. Building the Chemical and Biological Data Warehouse The project involves building tools and components which are to be used in building a Chemical and Biological Datawarehouse. This includes data modelling of the underlying structure, building of components for molecular and statistical calculations and development of the graphical user interface. As underlying technologies an Oracle database should be used as well as CORBA to build the computational components and JAVA to implement the graphical. The project will be done in collaboration with Novartis Pharma therefore strong communication skills are essential. Successfull candidates should have: - Enthusiasm - Strong computational background with fluency in two or more of the following programming languages Java, C, C++, perl, PL/SQL - Knowledge on relational databases (Oracle would be a plus) - Ph.D. in a relevant scientific field - Strong communication skills The position is open immediately for one year and may be renewed for one further year. During this time the candidate would: - Learn about the leading edge chemical data warehouse technology. - Gain proficiency in development of web based applications and distributed components. - Gain in-depth knowledge of relational database systems. For further information please send your resume to: ======================================================================== Dr. Alberto Gobbi Tel. +41 61 69 78465 Novartis Crop Protection AG Fax. +41 61 69 72540 WRO-1060.7.34 Alberto.Gobbi@Cp.Novartis.Com Postfach CH-4002 Basel Switzerland From owner-repertoires@net.bio.net Thu May 06 14:31:00 1999 Path: biosci!biosci!not-for-mail From: JONATHAN GERSON Newsgroups: bionet.molecules.repertoires Subject: Combinatorial Chemistry Event Date: 6 May 1999 08:31:29 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 33 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <37319295.CEF14344@ibcusa.com> NNTP-Posting-Host: net.bio.net IBC announces: 4th Annual Combinatorial Chemistry Conference - From Concept to Clinic June 28-29, 1999, Hilton La Jolla Torrey Pines, La Jolla, CA *Learn How Other Companies are Using Lead Optimization to Design Smarter Combinatorial Libraries *Hear Real Life Case study on how to implement a combinatorial chemistry program *Learn how to design smarter libraries *Discuss new tools and applications with leading organizations *Understand how data management and analysis can be used to improve your combinatorial chemistry program *Listen to top academics in the field Plus, a workshop on Ultra High-Throughput Screening All these topics and more at IBC's 4th Annual Combinatorial Chemistry Conference - From Concept to Clinic. June 28-29, 1999, La Jolla, CA. Space is filling up, reserve your place today. http://www.ibcusa.com/2353/source=moldiv Or for full conference brochure, contact Jonathan Gerson Marketing Team Leader IBC USA Conferences 225 Turnpike Road Southborough, MA 01772 508-481-6400 508-481-4473 www.ibcusa.com From owner-repertoires@net.bio.net Fri May 07 10:33:00 1999 Path: biosci!biosci!not-for-mail From: "Alexey V. Eliseev" Newsgroups: bionet.molecules.repertoires Subject: NATO ARW Molecular Diversity Date: 7 May 1999 04:33:02 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 40 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net Dear Colleagues, Prof. Nikolai Zefirov at the Moscow State University and I are happy to announce the upcoming NATO Advanced Research Workshop "FRONTIERS IN MOLECULAR DIVERSITY: FROM BIOLOGY TO MATERIAL SCIENCE". The meeting will be held in Moscow, Russia from September 19-22, 1999. We are coordinating our efforts with a small organizing committee that includes A. W. Czarnik and M. Famulok, to bring together a small but stimulating meeting that will cover new diversity-related directions in a broad range of disciplines. Our goal is to identify and discuss conceptually new and emerging approaches in the area of molecular diversity that may shape up into novel technologies in a few years down the road. The program of the meeting, application form, and some related links can be found on the workshop website at: http://www.pharm.buffalo.edu/events/NATO_ARW/ We will keep updating the site as the list of speakers gets finalized. If you have any workshop related questions, please email me at eliseev@acsu.buffalo.edu or fax at 1-716-645-2393. Alexey Eliseev ______________________________________________ Alexey V. Eliseev, Assistant Professor Department of Medicinal Chemistry State University of New York at Buffalo Buffalo, NY 14260, USA Ph.: 1-716-645-2872 Fax: 1-716-645-2393 Web: http://eliseev.bio.buffalo.edu From owner-repertoires@net.bio.net Wed May 12 10:12:00 1999 Path: biosci!biosci!not-for-mail From: "Dr. Wendy A. Warr" Newsgroups: bionet.molecules.repertoires Subject: New on Warr Zone Date: 12 May 1999 04:12:11 -0700 Organization: Wendy Warr & Associates Lines: 25 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <3736F379.21DB@warr.com> NNTP-Posting-Host: net.bio.net Latest headings on Warr Zone http://www.warr.com/warrzone.htm ChiroChem Discovery Services Announces Portfolio of Chiral Compounds CombiChem and Chromagen Sign Agreement CuraGen and Roche Sign Pharmacogenomics Agreement Thetagen Acquires Drug Discovery Services Chemical Hazards Communication Society E-mail Forum Green Chemistry Network New Board Appointments at Synopsys UKOLUG Moves Web Site Sandra Ward Joins TFPL Wendy -- Dr Wendy A Warr Wendy Warr & Associates, 6 Berwick Court Holmes Chapel, Cheshire CW4 7HZ, England Tel/fax +44 (0)1477 533837 wendy@warr.com http://www.warr.com From owner-repertoires@net.bio.net Thu May 13 07:35:00 1999 Path: biosci!biosci!not-for-mail From: Paul Brandl Newsgroups: bionet.molecules.repertoires Subject: Custom antibodies & peptide synthesis Date: 13 May 1999 01:35:27 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 37 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <01be9c94$f3d70340$347952c4@mbe015> NNTP-Posting-Host: net.bio.net Aurora Biomolecules Oriole Court 48 Regent St. Cambridge CB2 1FD www.biomolecules.co.uk Custom peptide & antibody synthesis. Aurora Biomolecules Oriole Court, 48 Regent St. Cambridge, England. CB2 1FD About Aurora Aurora Biomolecules is situated in the heart of Cambridge & specialises in polyclonal antibody production and peptide synthesis for academia, pharmaceutica and industry. Custom antibody production : £ 800 inclusive. a.. homology search & epitope prediction. b.. peptide synthesis. c.. conjugation to carrier protein d.. ELISA of all bleeds. Custom peptide synthesis : £ 30 per residue [ 20 mgs] . a.. peptide synthesis b.. HPLC purification c.. MALDI TOF analysis From owner-repertoires@net.bio.net Tue May 18 14:44:00 1999 Path: biosci!biosci!not-for-mail From: Fran Martin Newsgroups: bionet.molecules.repertoires Subject: Most Current U.S. CFRs on CD-ROM (incl. Title 21/food & drug) Date: 18 May 1999 08:44:53 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 18 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <2.2.32.19990517174008.006fb165@ccsinc.com> NNTP-Posting-Host: net.bio.net FYI for those who require instant access to U.S. regulations, The U.S. Code of Federal Regulations (all 50 Titles) updated to the latest 1998 revision levels are now available on CD-ROM. Features include no "time locks," 5,000+ in-line graphics, Adobe(R) Acrobat(R) PDF format, and instant search/retrieval. See http://www.env-sol.com/solutions/CFR.HTML for details. Fran Martin FM Research & Consulting From owner-repertoires@net.bio.net Wed May 19 16:25:00 1999 Path: biosci!biosci!not-for-mail From: "Dr. Wendy A. Warr" Newsgroups: bionet.molecules.repertoires Subject: Compounds for sale Date: 19 May 1999 10:25:08 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 11 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <3741A1EF.283C@warr.com> NNTP-Posting-Host: net.bio.net 10,000 compounds in microtiter plates for sale. Visit http://www.warr.com -- Dr Wendy A Warr Wendy Warr & Associates, 6 Berwick Court Holmes Chapel, Cheshire CW4 7HZ, England Tel/fax +44 (0)1477 533837 wendy@warr.com http://www.warr.com From owner-repertoires@net.bio.net Fri May 21 08:12:00 1999 Path: biosci!biosci!not-for-mail From: "Dr. Wendy A. Warr" Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 21 May 1999 02:12:04 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 32 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <374445E4.4592@warr.com> References: <19990520160036.15270.rocketmail@web1001.mail.yahoo.com> NNTP-Posting-Host: net.bio.net Chem Guy wrote: > > Warr, > > Why do you advertise your website or other content on these mailing > lists? > > a) it is inappropriate > b) it sets a precedent > > Stop this nonsense. I apologize to anyone, including "Chem Guy 23", who may have been offended by my message. Fortunately I have had lots of positive replies to my message and this reply was the only critical one. I am interested to hear subscribers' (and listowners') views on people who use pseudonyms to post this sort of reply. Wendy -- Dr Wendy A Warr Wendy Warr & Associates, 6 Berwick Court Holmes Chapel, Cheshire CW4 7HZ, England Tel/fax +44 (0)1477 533837 wendy@warr.com http://www.warr.com From owner-repertoires@net.bio.net Fri May 21 08:16:00 1999 Path: biosci!biosci!not-for-mail From: ASINEX Ltd Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 21 May 1999 02:16:43 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 41 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <01bea2ea$b6f4dc21$LocalHost@default> NNTP-Posting-Host: net.bio.net I agree with ChemGuy. We have maybe the largest open collection of hand-crafted organic compounds but Asinex does NOT advertise through academic mailing lists. Oleg Darakov http://www.asinex.com - >Chem Guy wrote: >> >> Warr, >> >> Why do you advertise your website or other content on these mailing >> lists? >> >> a) it is inappropriate >> b) it sets a precedent >> >> Stop this nonsense. > >I apologize to anyone, including "Chem Guy 23", who may have been >offended by my message. > >Fortunately I have had lots of positive replies to my message and this >reply was the only critical one. > >I am interested to hear subscribers' (and listowners') views on people >who use pseudonyms to post this sort of reply. > >Wendy >-- >Dr Wendy A Warr >Wendy Warr & Associates, 6 Berwick Court >Holmes Chapel, Cheshire CW4 7HZ, England >Tel/fax +44 (0)1477 533837 >wendy@warr.com http://www.warr.com > From owner-repertoires@net.bio.net Fri May 21 08:21:00 1999 Path: biosci!biosci!not-for-mail From: Asim Kumar Debnath Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 21 May 1999 02:21:13 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 32 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <9905201445.ZM6569@iris.nybc.org> References: <01bea2ea$b6f4dc21$LocalHost@default> NNTP-Posting-Host: net.bio.net You just did! This should not be a big deal, rather useful for academic/institute researchers who may be looking for economical databases of compounds for drug screening purpose. After learning from Wendy I enquired about it. I don to find it non-sense at all. Asim -- ======================================================================= *** *** Asim K. Debnath, Ph.D. **** Assistant Member **** Lindsley F. Kimball Research Institute **** *** The New York Blood Center **** **** 310 E 67 Th Street **** ** **** New York, NY 10021 **** **** **** Tel. (212) 570-3373 **** ** **** Fax. (212) 570-3299 **************** E-mail: adebnath@server.nybc.org ************** ======================================================================== From owner-repertoires@net.bio.net Fri May 21 08:25:00 1999 Path: biosci!biosci!not-for-mail From: Howard Zhang Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 21 May 1999 02:25:17 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 64 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <199905202011.NAA01426@smtp.abac.com> NNTP-Posting-Host: net.bio.net I think it is OK to post such a message. It benefits a lot of readers anyway. Howard Zhang, Ph.D. Combi-Blocks 7949 Silverton Avenue, Suite 915 San Diego, CA 92126 ---------------------------------------------------------------------------- -------------- Combi-Blocks, a worldwide supplier of combinatorial building blocks, resins and the best pricing/quality laboratory glassware for organic synthesis Phone: Toll free 1-877-5-blocks (1-877-525-6257) Phone: 619-635-8950 Fax: 619-635-8991 Fax: 619-587-8905 Online catalogs: http://www.combi-blocks.com -------------------------------------------------------------- ---------- > From: Dr. Wendy A. Warr > To: MOL-DIVERSITY@LISTSERV.ARIZONA.EDU > Subject: Re: Compounds for sale > Date: Thursday, May 20, 1999 10:27 > > Chem Guy wrote: > > > > Warr, > > > > Why do you advertise your website or other content on these mailing > > lists? > > > > a) it is inappropriate > > b) it sets a precedent > > > > Stop this nonsense. > > I apologize to anyone, including "Chem Guy 23", who may have been > offended by my message. > > Fortunately I have had lots of positive replies to my message and this > reply was the only critical one. > > I am interested to hear subscribers' (and listowners') views on people > who use pseudonyms to post this sort of reply. > > Wendy > -- > Dr Wendy A Warr > Wendy Warr & Associates, 6 Berwick Court > Holmes Chapel, Cheshire CW4 7HZ, England > Tel/fax +44 (0)1477 533837 > wendy@warr.com http://www.warr.com From owner-repertoires@net.bio.net Fri May 21 08:32:00 1999 Path: biosci!biosci!not-for-mail From: Bob Clark Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 21 May 1999 02:32:18 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 53 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <37447A26.DC961645@tripos.com> References: <19990520160036.15270.rocketmail@web1001.mail.yahoo.com> <374445E4.4592@warr.com> NNTP-Posting-Host: net.bio.net Wendy: Posting commercial information to lists can be very useful to subscribers but allowing it demands considerable discrimination and restraint from those who do so. It is an easy privilege to abuse - the economic incentive for sending out electronic junk mail which is of interest to only a tiny fraction of the list subscribers and an irritant to the rest is even more enormous than for the paper variety. So far as I can recall, you yourself have always has been careful to post useful information and avoid advertisement. So long as everyone is equally discriminating, there should be no problem. Bob Clark "Dr. Wendy A. Warr" wrote: > Chem Guy wrote: > > > > Warr, > > > > Why do you advertise your website or other content on these mailing > > lists? > > > > a) it is inappropriate > > b) it sets a precedent Wendy Warr wrote: > Fortunately I have had lots of positive replies to my message and this > reply was the only critical one. > > I am interested to hear subscribers' (and listowners') views on people > who use pseudonyms to post this sort of reply. It seems to me that the pseudonym might be appropriate, for example, for an individual working at a company which encourages abuse of the privilege. > > Wendy > -- > Dr Wendy A Warr > Wendy Warr & Associates, 6 Berwick Court > Holmes Chapel, Cheshire CW4 7HZ, England > Tel/fax +44 (0)1477 533837 > wendy@warr.com http://www.warr.com From owner-repertoires@net.bio.net Fri May 21 08:42:00 1999 Path: biosci!biosci!not-for-mail From: george sibbald Newsgroups: bionet.molecules.repertoires Subject: Poster / Images: Protein folding force characterization via AFM Date: 21 May 1999 02:42:17 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 18 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <02d601bea319$c69647c0$74c0dad2@george> NNTP-Posting-Host: net.bio.net Poster / Images: Protein folding force characterization via AFM Biological Measurements and Forces in MAC Mode AFM Stuart Lindsay, Wenhai Han, and Yanzhang Liu; ASU Biological force measurements and the AFM Protein unfolding may play a vital role in protein function (Soteriou, Clarke et al. 1993). Last year, Rief et al. (Rief, Gautel et al. 1997) demonstrated that the AFM could be used to follow the unfolding of a single protein molecule trapped between the AFM probe and a gold surface http://www.molec.com/newsletters/spring98/npage1.htm From owner-repertoires@net.bio.net Fri May 21 08:43:00 1999 Path: biosci!biosci!not-for-mail From: Keith.Rose@medecine.unige.ch (Keith Rose) Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 21 May 1999 02:43:52 -0700 Organization: MRC Human Genome Mapping Project Resource Centre Lines: 42 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <3.0.1.32.19990521111837.00abc9a0@cmu.unige.ch> NNTP-Posting-Host: net.bio.net I think that advertising is inappropriate and I too wish you would stop. At 02:12 AM 5/21/99 -0700, you wrote: >Chem Guy wrote: >> >> Warr, >> >> Why do you advertise your website or other content on these mailing >> lists? >> >> a) it is inappropriate >> b) it sets a precedent >> >> Stop this nonsense. > >I apologize to anyone, including "Chem Guy 23", who may have been >offended by my message. > >Fortunately I have had lots of positive replies to my message and this >reply was the only critical one. > >I am interested to hear subscribers' (and listowners') views on people >who use pseudonyms to post this sort of reply. > >Wendy >-- >Dr Wendy A Warr >Wendy Warr & Associates, 6 Berwick Court >Holmes Chapel, Cheshire CW4 7HZ, England >Tel/fax +44 (0)1477 533837 >wendy@warr.com http://www.warr.com > > > > > --- From owner-repertoires@net.bio.net Mon May 24 07:57:00 1999 Path: biosci!biosci!not-for-mail From: "Dr. Duncan Clark" Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 24 May 1999 01:57:48 -0700 Organization: DNAmp Ltd. Lines: 35 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: References: <19990520160036.15270.rocketmail@web1001.mail.yahoo.com> <374445E4.4592@warr.com> Reply-To: "Dr. Duncan Clark" NNTP-Posting-Host: net.bio.net In article <374445E4.4592@warr.com>, Dr. Wendy A. Warr writes >Fortunately I have had lots of positive replies to my message and this >reply was the only critical one. But that still doesn't make it right! It was still SPAM. I think you will find that the charter for all bionet newsgroups specifically prohibits this kind of advertising. It is certainly mentioned in FAQ's for other bionet newsgroups. If it was allowed, can you imagine how bad it would get. Adverts cross- posted to all bionet groups for every product from every biotech company. Thousands of posts a week, all of which would have to be filtered out by the reader. Given that a lot of readers still do not use a news reader but subscribe by e-mail, their e-mail servers would get clogged up very quickly. There would then be an immediate demand to make all these groups moderated with all that entails. Duncan -- The problem with being on the cutting edge is that you occasionally get sliced from time to time.... Duncan Clark DNAmp Ltd. Tel: +44(0)1252376288 FAX: +44(0)8701640382 http://www.dnamp.com http://www.genesys.demon.co.uk From owner-repertoires@net.bio.net Mon May 24 08:12:00 1999 Path: biosci!biosci!not-for-mail From: Jim Qiu Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 24 May 1999 02:12:52 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 73 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <3.0.5.32.19990523231933.007c6731@syncommbdl.com> NNTP-Posting-Host: net.bio.net This guy loves the product! Please help us to become an exclusive buyer of Dr. Warr's product. Don't bother me! ---------------- At 01:07 PM 5/20/1999 -0700, you wrote: >I think it is OK to post such a message. It benefits a lot of readers >anyway. > > >Howard Zhang, Ph.D. >Combi-Blocks >7949 Silverton Avenue, Suite 915 >San Diego, CA 92126 >---------------------------------------------------------------------------- >-------------- >Combi-Blocks, a worldwide supplier of combinatorial building blocks, resins >and the best >pricing/quality laboratory glassware for organic synthesis > >Phone: Toll free 1-877-5-blocks (1-877-525-6257) > >Phone: 619-635-8950 >Fax: 619-635-8991 >Fax: 619-587-8905 > >Online catalogs: http://www.combi-blocks.com >-------------------------------------------------------------- > > > > >---------- >> From: Dr. Wendy A. Warr >> To: MOL-DIVERSITY@LISTSERV.ARIZONA.EDU >> Subject: Re: Compounds for sale >> Date: Thursday, May 20, 1999 10:27 >> >> Chem Guy wrote: >> > >> > Warr, >> > >> > Why do you advertise your website or other content on these mailing >> > lists? >> > >> > a) it is inappropriate >> > b) it sets a precedent >> > >> > Stop this nonsense. >> >> I apologize to anyone, including "Chem Guy 23", who may have been >> offended by my message. >> >> Fortunately I have had lots of positive replies to my message and this >> reply was the only critical one. >> >> I am interested to hear subscribers' (and listowners') views on people >> who use pseudonyms to post this sort of reply. >> >> Wendy >> -- >> Dr Wendy A Warr >> Wendy Warr & Associates, 6 Berwick Court >> Holmes Chapel, Cheshire CW4 7HZ, England >> Tel/fax +44 (0)1477 533837 >> wendy@warr.com http://www.warr.com > > From owner-repertoires@net.bio.net Mon May 24 08:23:00 1999 Path: biosci!biosci!not-for-mail From: Linda Fei Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 24 May 1999 02:23:00 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 49 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <3.0.5.32.19990521194815.007a5c91@syncommbdl.com> NNTP-Posting-Host: net.bio.net Warr should not adverstise his product on our academic mail lists. we are watching him. Linda Fei ----------- At 10:00 PM 5/20/1999 +0400, you wrote: >I agree with ChemGuy. We have maybe the largest open >collection of hand-crafted organic compounds but Asinex >does NOT advertise through academic mailing lists. > >Oleg Darakov >http://www.asinex.com >- > >>Chem Guy wrote: >>> >>> Warr, >>> >>> Why do you advertise your website or other content on these mailing >>> lists? >>> >>> a) it is inappropriate >>> b) it sets a precedent >>> >>> Stop this nonsense. >> >>I apologize to anyone, including "Chem Guy 23", who may have been >>offended by my message. >> >>Fortunately I have had lots of positive replies to my message and this >>reply was the only critical one. >> >>I am interested to hear subscribers' (and listowners') views on people >>who use pseudonyms to post this sort of reply. >> >>Wendy >>-- >>Dr Wendy A Warr >>Wendy Warr & Associates, 6 Berwick Court >>Holmes Chapel, Cheshire CW4 7HZ, England >>Tel/fax +44 (0)1477 533837 >>wendy@warr.com http://www.warr.com >> > > From owner-repertoires@net.bio.net Mon May 24 14:31:00 1999 Path: biosci!biosci!not-for-mail From: "Dr. Wendy A. Warr" Newsgroups: bionet.molecules.repertoires Subject: Re: Compounds for sale Date: 24 May 1999 08:31:48 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 51 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <374953EE.7AC@warr.com> References: <3.0.5.32.19990523231933.007c6730@syncommbdl.com> NNTP-Posting-Host: net.bio.net Jim Qiu wrote: > > This guy loves the product! Please help us to become an exclusive buyer of > Dr. Warr's product. > > Don't bother me! > Apologies for duplication and for the length of this message... Dr. Qui, I do not have a "product". I am a consultant. I run a *free* news column, and *free* events listings on my Web site (whose URL I will not cite here) and also a *free* molecular diversity resources listing, and also *free* reports on various meetings. Lots of people find these free services useful. I am sorry that you do not. I cannot please everyone. Recently, as a favor to a colleague, I sent a one line message, without price or sales hype, about compounds for sale. The message was well within the guidelines for "ads" on most list servers but it offended a lurker who sent a message without the courtesy of putting his or her name to it. I have had lots of messages about this recently (fortunately for you, most of them to me personally, not to the whole list). It is clear that the majority of respondents DO find my messages useful. Since you do not, please can you bear to delete my messages without reading them so that other subscribers can benefit. As I said, I cannot please everyone. These three lists are by no means "busy". Deleting, say, two messages a month cannot be arduous. I am not in the business of selling compounds and I do not intend to do so in future. I have now decided to place no further messages of any sort on the isisforum-l list unless they very specifically concern ISIS. Subscribers to that list who want to hear from me about conferences, travel grants, etc. will need to subscribe to another list. My thanks to all the nice people who sent me encouraging messages. I will attempt to follow the suggestions of those who sent constructive criticism. Can I suggest that this correspondence now be closed? Wendy Warr From owner-repertoires@net.bio.net Wed May 26 07:03:00 1999 Path: biosci!biosci!not-for-mail From: Michael Sherrell Newsgroups: bionet.molecules.repertoires Subject: MS, seqs, synths, NMRs for sale Date: 26 May 1999 01:03:14 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 59 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <01BEA6EC.F0FF2BE0@user-33qsohi.dialup.mindspring.com> NNTP-Posting-Host: net.bio.net Mass spectrometers, sequencers, synthesizers, NMRs for sale: LC/Mass spectrometers: Sciex API III+ LC/MS/MS $ 69,000 ES, APCI, under PE service = contract HP 1100 benchtop LC/MSD, APCI & API-electrospray, autosampler, DAD = detector, < 1 year old, $130,000 Finnigan Navigator benchtop LC/MS: $ 75,000; 18 mos. old; factory = refurb, install & 90-day warr. included Finnigan TSQ 7000 LC+GC/MS/MS: $ 97,500; current software; API-1 = source; under Finnigan service contract Sciex 150 benchtop LC/MS: $ 98,000; 2 yrs old; includes Gilson 215 = liquid handler, ELSD detector & HP 1100 HPLC. Finnigan SSQ 7000 LC/MS: $130,000; API-2 source, electrospray + = APCI, Excaliber software, factory refurb, 90-day warranty, install = included Micromass II: $50,000; ES, APCI, 3 yrs. old, includes HPLC, NOT = Z-spray HP 5989B LC+GC/MS: $ 35,000; Extended mass range (2000 amu), hex = ion guide; HPLC & warranty avail. Finnigan MAT 90: $30,000; Hi-resolution magnetic sector Fisons VG 2000: <$100,000 MALDI-TOFs: Hewlett-Packard G2025A $ 50,000 Peptide and oligo synthesizers and sequencers: ABI 394: $12,500 (Valve blocks rebuilt; warranteed) ABI 390Z: $4,000 (50-100uM yields) ABI 431: $12,500 (Rebuilt, warranteed) ABI 433: $19,000 (ABI upgrade) PerSeptive 9050+: $6,000 (As is/was working when decommissioned; = add $3,500 for rebuild/warranty) ABI 373 stretch: $9,000 (Big dye upgrade; still under warranty) ABI 373 stretch: $7,000 (4-filter) ABI 377: $97,500 (XL; 96 lanes; transferrable ABI service contract) ABI 377: $60,000 (48-lane; under ABI contract) ABI Procise 492: $45,000 obo (ABI-certified) NMRs: =A0=A0=A0 Bruker DMX 600: $495,000; AVANCE; 3-axis gradients =A0=A0=A0 Varian Unity 500+: call for price; broadband =A0=A0=A0 Bruker AM360: $85,000; broadband; widebore; install included =A0=A0=A0 Varian Gemini 300: call for price; widebore; broadband; = remote sampling arm; ~1992 =A0=A0=A0 Varian Gemini 300: $69,000; proton/carbon probe; freight, = install, 90-day warr. included =A0=A0=A0 Varian Unity 500: call for price; broadband Also available: Hitachi 570 scanning electron microscope, Kevex detector, running = now, $35,000. BD FACSVantage and assorted FACScans Various other seqencers, synthesizers etc. are available; please inquire = or check the website. Michael Sherrell Grizzly Analytical 707 887 2919/fax 707 887 9834 www.grizzlyanalytical.com =00 From owner-repertoires@net.bio.net Wed May 26 07:20:00 1999 Path: biosci!biosci!not-for-mail From: ELLEN MASSA Newsgroups: bionet.molecules.repertoires Subject: Special Offer - 50% Off Combinatorial Chemistry Conference Date: 26 May 1999 01:20:00 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 62 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <8OGWNSP4.61BBY947@ibcusa.com> NNTP-Posting-Host: net.bio.net IBC's Combinatorial Chemistry Conference - http://www.ibcusa.com/2353/?source=em3 June 28-29, 1999, Hilton La Jolla Torrey Pines, La Jolla, CA SPECIAL OFFER: RECEIVE 50% OFF THE REGISTRATION FEE! ***************************************************** Can you afford to miss out on the latest combinatorial chemistry information? This years Combinatorial Chemistry conference includes over 20 experts to discuss: * 4 "Real Life" Case Studies * Focus Libraries and Lead Optimization * Data Management and Analysis * New Tools and Applications with Leading Organizations * Ultra High-Throughput Screening also! 6 confirmed exhibitors: ** American Chemical Society ** GeneVac/BioVac ** PE Biosystems ** Pharm-Eco Laboratories ** Robbins Scientific ** Whatman Polyfiltronics To receive the 50% off simply enter the reference code "CCEM3" in the keycode section of the registration page http://www.ibcusa.com/2353/?source=em3 Don't miss out - register today!!! **** Drug and Market Development Publications - now online Visit http://www.drugandmarket.com - Bookmark it today! **** Hear the latest Drug Discovery Information at the World's Drug Discovery Meeting Place IBC's 4th Annual Drug Discovery Technology Exposition and Symposium. August 16-19, 1999, Boston, MA Over 1,000 attendees and 150 exhibitors - visit our virtual exhibit hall today! http://www.drugdisc.com **************** Ellen Massa Marketing Manager IBC USA Conferences 225 Turnpike Road Southborough, MA 01772 508-481-6400 x440 508-481-4473 emassa@ibcusa.com **************** From owner-repertoires@net.bio.net Wed May 26 08:29:00 1999 Path: biosci!biosci!not-for-mail From: Steve Heller Newsgroups: bionet.molecules.repertoires Subject: ChemInt'99 - June 1 Abstract Submission Deadine/Web Site searchable Date: 26 May 1999 02:29:23 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 70 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net The Chemistry & the Internet web site is now keyword searchable.. All of the ChemInt'98 presentations on the web site can be searched. Go to www.chemint.org This note is to also announce that the deadline for poster abstract submissions to be considered for oral presentations at the ChemInt'99 meeting is June 1. Abstracts submitted after June 1 will be accepted, but only as poster talks. The Chemistry and the Internet (ChemInt'99) meeting being held in at Georgetown University in Washington DC on September 25-27, 1999. The program of invited speakers and panel members of the 3 panel sessions is available on the meeting web site - www.chemint.org You are urged to look at the program and to consider submitting a poster paper to the meeting. A number of poster papers will be selected in mid-June for oral presentation at the meeting. The main lecturers for the meeting will be: Alan Arnold, University College (UNSW) Steven Bachrach, Northern Illinois University Robert Bovenschulte, ACS Stephen Boyer, IBM Karl Harrison, Oxford University Clemens Jochum, Deutsche Bank Gary Mallard, NIST Tom Pierce, Rohm & Haas Jerome Reichman, Vanderbilt Achim Zielesny, Bayer AG Steven S. Zumdahl, University of Illinois at Urbana-Champaign The (current) corporate sponsors for the meeting are: ChemWeb and the Internet Journal of Chemistry Technical Sponsors are: ACS CINF Division ACS COMP Division The Chemical Structure Association (CSA) Georgetown University - Department of Chemistry International Union of Pure and Applied Chemistry (IUPAC) (pending) Japan Association for International Chemical Information (JAICI) Special Libraries Association (SLA) Chemistry Division Royal Society of Chemistry (RSC) Steve Heller Steve Heller, Guest Researcher NIST/SRD, Mail Stop: 820/113 820 Diamond Avenue, Room 101 Gaithersburg, MD 20899-2310 USA E-mail: chem@feldmann.nist.gov